1
|
Volk J, Huntington J, Melton F, Minor B, Wang T, Anapalli S, Anderson R, Evett S, French A, Jasoni R, Bambach N, Kustas W, Alfieri J, Prueger J, Hipps L, McKee L, Castro S, Alsina M, McElrone A, Reba M, Runkle B, Saber M, Sanchez C, Tajfar E, Allen R, Anderson M. Post-processed data and graphical tools for a CONUS-wide eddy flux evapotranspiration dataset. Data Brief 2023; 48:109274. [PMID: 37383786 PMCID: PMC10294113 DOI: 10.1016/j.dib.2023.109274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Revised: 05/02/2023] [Accepted: 05/23/2023] [Indexed: 06/30/2023] Open
Abstract
Large sample datasets of in situ evapotranspiration (ET) measurements with well documented data provenance and quality assurance are critical for water management and many fields of earth science research. We present a post-processed ET oriented dataset at daily and monthly timesteps, from 161 stations, including 148 eddy covariance flux towers, that were chosen based on their data quality from nearly 350 stations across the contiguous United States. In addition to ET, the data includes energy and heat fluxes, meteorological measurements, and reference ET downloaded from gridMET for each flux station. Data processing techniques were conducted in a reproducible manner using open-source software. Most data initially came from the public AmeriFlux network, however, several different networks (e.g., the USDA-Agricultural Research Service) and university partners provided data that was not yet public. Initial half-hourly energy balance data were gap-filled and aggregated to daily frequency, and turbulent fluxes were corrected for energy balance closure error using the FLUXNET2015/ONEFlux energy balance ratio approach. Metadata, diagnostics of energy balance, and interactive graphs of time series data are included for each station. Although the dataset was developed primarily to benchmark satellite-based remote sensing ET models of the OpenET initiative, there are many other potential uses, such as validation for a range of regional hydrologic and atmospheric models.
Collapse
Affiliation(s)
- J.M. Volk
- Desert Research Institute, 2215 Raggio Pkwy, Reno, NV 89512 USA
| | - J.L. Huntington
- Desert Research Institute, 2215 Raggio Pkwy, Reno, NV 89512 USA
| | - F. Melton
- NASA Ames Research Center, Mail Stop 245-1, Moffett Field, CA 94035-1000 USA
- California State University, Monterey Bay, Seaside, CA 93955 USA
| | - B. Minor
- Desert Research Institute, 2215 Raggio Pkwy, Reno, NV 89512 USA
| | - T. Wang
- University of California, Berkeley, Berkeley, CA 94720 USA
| | - S. Anapalli
- USDA-ARS, Sustainable Water Management Research Unit, 4006 Old Leland Road, Stoneville, MS 38776 USA
| | - R.G. Anderson
- USDA-ARS US Salinity Laboratory, Agricultural Water Efficiency and Salinity Research Unit, 450 W Big Springs Rd Riverside, CA 92507-4617 USA
| | - S. Evett
- USDA-ARS Conservation & Production Research Laboratory, 300 Simmons Road, Bushland, TX 79012 USA
| | - A. French
- USDA-ARS US Arid-Land Agricultural Research Center, 21881 North Cardon Lane, Maricopa, AZ, 85238 USA
| | - R. Jasoni
- Desert Research Institute, 2215 Raggio Pkwy, Reno, NV 89512 USA
| | - N. Bambach
- University of California, Davis, CA 95616 USA
| | - W.P. Kustas
- USDA-ARS Hydrology and Remote Sensing Laboratory, Bldg. 007, Rm. 104, BARC-West, Beltsville, MD 20705-2350 USA
| | - J. Alfieri
- USDA-ARS Hydrology and Remote Sensing Laboratory, Bldg. 007, Rm. 104, BARC-West, Beltsville, MD 20705-2350 USA
| | - J. Prueger
- USDA-ARS National Laboratory for Agriculture and The Environment, 1015 N. University Blvd., AMES, IA 50011 USA
| | - L. Hipps
- Utah State University, Logan, UT 84322-0102 USA
| | - L. McKee
- USDA-ARS Hydrology and Remote Sensing Laboratory, Bldg. 007, Rm. 104, BARC-West, Beltsville, MD 20705-2350 USA
| | - S.J. Castro
- USDA-ARS US Salinity Laboratory, Agricultural Water Efficiency and Salinity Research Unit, 450 W Big Springs Rd Riverside, CA 92507-4617 USA
| | - M.M. Alsina
- E & J Gallo Winery, Viticulture, Chemistry and Enology, Modesto, CA USA
| | - A.J. McElrone
- Utah State University, Logan, UT 84322-0102 USA
- USDA-ARS Crops Pathology and Genetics Research Unit, Davis, CA, 95616 USA
| | - M. Reba
- USDA-ARS Delta Water Management Research, Jonesboro, AR, 72401 USA
| | - B. Runkle
- University of Arkansas, Fayetteville, AR 72701 USA
| | - M. Saber
- University of Arizona, Tucson, AZ 85721 USA
| | - C. Sanchez
- University of Arizona, Tucson, AZ 85721 USA
| | - E. Tajfar
- University of Arkansas, Fayetteville, AR 72701 USA
| | - R. Allen
- University of Idaho, Moscow, ID 83844 USA
- University of Nebraska-Lincoln, Lincoln, NE 68588 USA
| | - M. Anderson
- USDA-ARS Hydrology and Remote Sensing Laboratory, Bldg. 007, Rm. 104, BARC-West, Beltsville, MD 20705-2350 USA
| |
Collapse
|
2
|
Barril G, Nogueira Pérez Á, Álvarez G, Nuñez A, Cabrera A, Sanchez C, Ruperto M. Assessment Of Muscular Strength In Patients With Chronic Kidney Disease, Dynamometry Or Cell Mass Index. Clin Nutr ESPEN 2023. [DOI: 10.1016/j.clnesp.2022.09.276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/28/2023]
|
3
|
Gonzalez Boillos M, Castro de la Vega I, Chiva Martinez M, Pla Peris B, Abellan P, Maravall F, Merchante Alfaro A, Perez Naranjo S, Sanchez C. Correlation Between Bioimpedanciometry (BI) And Femoral Anterior Rectus Muscular Ultrasound Study (US) In Outpatients Submitted For Pre- And Post-Radical Cystectomy Evaluation. Clin Nutr ESPEN 2023. [DOI: 10.1016/j.clnesp.2022.09.199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
|
4
|
Cecchi M, Adachi M, Basile A, Buhl DL, Chadchankar H, Christensen S, Christian E, Doherty J, Fadem KC, Farley B, Forman MS, Honda S, Johannesen J, Kinon BJ, Klamer D, Marino MJ, Missling C, O'Donnell P, Piser T, Puryear CB, Quirk MC, Rotte M, Sanchez C, Smith DG, Uslaner JM, Javitt DC, Keefe RSE, Mathalon D, Potter WZ, Walling DP, Ereshefsky L. Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers. Schizophr Res 2023; 254:178-189. [PMID: 36921403 DOI: 10.1016/j.schres.2023.02.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2022] [Revised: 11/23/2022] [Accepted: 02/10/2023] [Indexed: 03/18/2023]
Abstract
OBJECTIVE Complexity and lack of standardization have mostly limited the use of event-related potentials (ERPs) and quantitative EEG (QEEG) biomarkers in drug development to small early phase trials. We present results from a clinical study on healthy volunteers (HV) and patients with schizophrenia (SZ) that assessed test-retest, group differences, variance, and correlation with functional assessments for ERP and QEEG measures collected at clinical and commercial trial sites with standardized instrumentation and methods, and analyzed through an automated data analysis pipeline. METHODS 81 HV and 80 SZ were tested at one of four study sites. Subjects were administered two ERP/EEG testing sessions on separate visits. Sessions included a mismatch negativity paradigm, a 40 Hz auditory steady-state response paradigm, an eyes-closed resting state EEG, and an active auditory oddball paradigm. SZ subjects were also tested on the Brief Assessment of Cognition (BAC), Positive and Negative Syndrome Scale (PANSS), and Virtual Reality Functional Capacity Assessment Tool (VRFCAT). RESULTS Standardized ERP/EEG instrumentation and methods ensured few test failures. The automated data analysis pipeline allowed for near real-time analysis with no human intervention. Test-retest reliability was fair-to-excellent for most of the outcome measures. SZ subjects showed significant deficits in ERP and QEEG measures consistent with published academic literature. A subset of ERP and QEEG measures correlated with functional assessments administered to the SZ subjects. CONCLUSIONS With standardized instrumentation and methods, complex ERP/EEG testing sessions can be reliably performed at clinical and commercial trial sites to produce high-quality data in near real-time.
Collapse
Affiliation(s)
| | | | - A Basile
- Merck & Co., Inc., Kenilworth, NJ, USA
| | | | | | | | | | | | | | | | | | | | | | | | - D Klamer
- Anavex Life Sciences Corp., NY, USA
| | | | | | | | - T Piser
- Onsero Therapeutics, MA, USA
| | | | | | | | | | | | | | | | | | - D Mathalon
- University of California, San Francisco, CA, USA
| | - W Z Potter
- Independent Consultant, Philadelphia, PA, USA
| | | | - L Ereshefsky
- CenExel Research, USA; University of Texas Health Science Center at San Antonio, TX, USA
| |
Collapse
|
5
|
Singer P, De Waele E, Sanchez C, Ruiz Santana S, Montejo JC, Laterre PF, Soroksky A, Moscovici E, Kagan I. Erratum to "TICACOS international: A multi-center, randomized, prospective controlled study comparing tight calorie control versus liberal calorie administration study" (1). Clin Nutr 2023; 42:440-441. [PMID: 36690567 DOI: 10.1016/j.clnu.2022.12.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- P Singer
- Department of Intensive Care, Institute for Nutrition Research, Rabin Medical Center, Beillison Hospital, affiliated to the Sackler School of Medicine, Tel Aviv University, Israel.
| | - E De Waele
- Department of Surgical ICU, UZ Brussel, Belgium.
| | - C Sanchez
- Hospital General Reina Sofía, Murcia, Spain.
| | - S Ruiz Santana
- Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain
| | - J C Montejo
- Hospital Universitario 12 de Octubre, Madrid, Spain.
| | | | - A Soroksky
- Intensive Care Unit, Wolfson Medical Center, Holon, Israel.
| | - E Moscovici
- Department of Intensive Care, Institute for Nutrition Research, Rabin Medical Center, Beillison Hospital, affiliated to the Sackler School of Medicine, Tel Aviv University, Israel
| | - I Kagan
- Department of Intensive Care, Institute for Nutrition Research, Rabin Medical Center, Beillison Hospital, affiliated to the Sackler School of Medicine, Tel Aviv University, Israel
| |
Collapse
|
6
|
Chahin JJA, Morales CG, Cordero HO, Rosario LT, Sanchez C. Mimicking an invasive fungal infection: an atypical presentation of herpes simplex virus type 1 in a neutropenic patient. Am J Med Sci 2023. [DOI: 10.1016/s0002-9629(23)00276-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
7
|
Mehta S, Vieira D, Guillen V, Zerpa D, Quintana A, Sanchez C, Ozair S, Brena-Pastor L, Pinos D, Fleming M, Carrera K, Rossitto F, Martinez F, Gonzalez A, Rodriguez K. Artificial intelligence-guided, single-lead EKG may be a game-changer for symptom-to-balloon time reduction in ST-elevated myocardial infarction. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Over decades, efforts to shave off life-saving minutes from ST-Elevated Myocardial Infarction (STEMI) care centred on reducing door-to-needle and door-to-balloon times. We firmly believe that symptom-to-balloon time should prove a better focus to this end. Challenges come with this goal as it heavily relies on a patient's perception and initiative to seek care, which we deem intelligent and wearable Artificial Intelligence (AI)-driven Single Lead EKG technologies as an attractive solution in modern-day cardiology.
Purpose
To provide an accurate, accessible, and cost-effective AI-driven Single Lead STEMI detection algorithm that can be embedded into wearable devices and employed in a self-administered fashion.
Methods
Database: EKG records from Mexico, Colombia, Argentina, and Brazil from April 2014 to December 2019. Dataset: A total of 11,567 12-lead EKG records of 10[s] length with a sampling frequency of 500 Hz, including the following balanced classes: angiographically confirmed and unconfirmed STEMI, branch blocks, non-specific ST-T abnormalities, normal and abnormal (200+ CPT codes, excluding those mentioned above). Cardiologists manually checked the label of each record to ensure precision. Pre-processing: We discard the first and last 250 samples as they may contain a standardisation pulse. The study applied a digital low pass filter of order 5 with a frequency cut-off of 35 Hz. The mean was subtracted from each Lead. Classification: The determined classes were “STEMI” (Including STEMI in different locations of the myocardium – anterior, inferior, and lateral); and “Not-STEMI” (Combination of randomly sample, branch blocks, non-specific ST-T changes, and abnormal records – 25% of each). Training and Testing: A 1-D Convolutional Neural Network was trained and tested with a dataset proportion of 90/10, respectively. A different model was trained and tested for each Lead, using the central 4,500 samples of the records. The last dense layer outputs a probability for each report of being STEMI or Not-STEMI. Lead V2 showed the best overall results. The model was further tested through the same methodology using the best Lead with a subset of the previous data, excluding the unconfirmed STEMI EKG records (Total 7,230 12-lead EKG records for Confirmed Only STEMI dataset). Performance metrics were reported for each experiment and compared.
Results
Combined STEMI data: Accuracy: 91.2%; Sensitivity: 89.6%; Specificity: 92.9%. Confirmed STEMI Only dataset: Accuracy: 92.4%; Sensitivity: 93.4%; Specificity: 91.4% (Figure 1).
Conclusion
By assiduously improving the quality of the model's input, we continue to assess our algorithm's performance and reliability for future clinical validation as a potential remote monitoring and early STEMI detection device.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- S Mehta
- Lumen Foundation , Miami , United States of America
| | - D Vieira
- Lumen Foundation , Miami , United States of America
| | - V Guillen
- Lumen Foundation , Miami , United States of America
| | - D Zerpa
- Lumen Foundation , Miami , United States of America
| | - A Quintana
- Lumen Foundation , Miami , United States of America
| | - C Sanchez
- Lumen Foundation , Miami , United States of America
| | - S Ozair
- Lumen Foundation , Miami , United States of America
| | | | - D Pinos
- Lumen Foundation , Miami , United States of America
| | - M Fleming
- Lumen Foundation , Miami , United States of America
| | - K Carrera
- Lumen Foundation , Miami , United States of America
| | - F Rossitto
- Lumen Foundation , Miami , United States of America
| | - F Martinez
- Lumen Foundation , Miami , United States of America
| | - A Gonzalez
- Lumen Foundation , Miami , United States of America
| | - K Rodriguez
- Lumen Foundation , Miami , United States of America
| |
Collapse
|
8
|
Segond N, Bellier A, Duhem H, Sanchez C, Busi O, Deutsch S, Aguilera L, Truan D, Koch FX, Viglino D, Debaty G. Supraglottic airway device to improve ventilation success and reduce pulmonary aspiration during cardio-pulmonary resuscitation by basic life support rescuers: a randomised cross-over human cadaver study. PREHOSP EMERG CARE 2022:1-9. [PMID: 35543652 DOI: 10.1080/10903127.2022.2075994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Objectives: Early airway management during cardiopulmonary resuscitation (CPR) prevents aspiration of gastric contents. Endotracheal intubation is the gold standard to protect airways, but supraglottic airway devices (SGA) may provide some protection with less training. Bag-mask ventilation (BMV) is the most common method used by rescuers. We hypothesized that SGA use by first rescuers during CPR could increase ventilation success rate and also decrease intragastric pressure and pulmonary aspiration.Methods: We performed a randomized cross-over experimental trial on human cadavers. Protocol A: we assessed the rate of successful ventilation (chest rise), intragastric pressure, and CPR key time metrics. Protocol B: cadaver stomachs were randomized to be filled with 300 mL of either blue or green serum saline solution through a Foley catheter. Each rescuer was randomly assigned to use SGA or BMV during a 5-minute standard CPR period. Then, in a crossover design, the stomach was filled with the second colour solution and another 5-minute CPR period was performed using the other airway method. Pulmonary aspiration, defined as the presence of coloured solution below the vocal cords, was assessed by a blinded operator using bronchoscopy. A generalized linear mixed model was used for statistical analysis.Results: Protocol A: Forty-eight rescuers performed CPR on 11 cadavers. Median ventilation success was higher with SGA than BMV: 75.0% (IQR: 59.8-87.3) vs. 34.7% (IQR: 25.0-50.0), (p = 0.003). Gastric pressure and differential (maximum minus minimum) gastric pressure were lower in the SGA group: 2.21 mmHg (IQR: 1.66; 2.68) vs. 3.02 mmHg (IQR: 2.02; 4.22) (p = 0.02) and 5.70 mmHg (IQR: 4.10; 7.60) vs. 8.05 mmHg (IQR: 5.40; 11.60) (p = 0.05). CPR key times were not different between groups. Protocol B: Ten cadavers were included with 20 CPR periods. Aspiration occurred in 2 (20%) SGA procedures and 5 (50%) BMV procedures (p = 0.44).Conclusion: Use of SGA by rescuers improved the ventilation success rate, decreased intragastric pressure, and did not affect key CPR metrics. SGA use by basic life support rescuers appears feasible and efficient.
Collapse
Affiliation(s)
- N Segond
- Emergency Department and Mobile Intensive Care Unit, University Hospital of Grenoble Alpes, Grenoble, France.,CNRS TIMC Laboratory, UMR 5525, Univ. Grenoble Alpes, Grenoble, France
| | - A Bellier
- CNRS TIMC Laboratory, UMR 5525, Univ. Grenoble Alpes, Grenoble, France.,LADAF-Laboratoire d'Anatomie Des Alpes Françaises, Univ. Grenoble Alpes, Grenoble, France
| | - H Duhem
- Emergency Department and Mobile Intensive Care Unit, University Hospital of Grenoble Alpes, Grenoble, France.,CNRS TIMC Laboratory, UMR 5525, Univ. Grenoble Alpes, Grenoble, France
| | - C Sanchez
- Emergency Department and Mobile Intensive Care Unit, University Hospital of Grenoble Alpes, Grenoble, France
| | - O Busi
- Emergency Department and Mobile Intensive Care Unit, University Hospital of Grenoble Alpes, Grenoble, France
| | - S Deutsch
- Emergency Department and Mobile Intensive Care Unit, University Hospital of Grenoble Alpes, Grenoble, France
| | - L Aguilera
- Emergency Department and Mobile Intensive Care Unit, University Hospital of Grenoble Alpes, Grenoble, France
| | - D Truan
- Emergency Department and Mobile Intensive Care Unit, University Hospital of Grenoble Alpes, Grenoble, France
| | - F X Koch
- Emergency Department and Mobile Intensive Care Unit, University Hospital of Grenoble Alpes, Grenoble, France
| | - D Viglino
- Emergency Department and Mobile Intensive Care Unit, University Hospital of Grenoble Alpes, Grenoble, France.,INSERM U1300, HP2 Laboratory, Univ. Grenoble Alpes, Grenoble, France
| | - G Debaty
- Emergency Department and Mobile Intensive Care Unit, University Hospital of Grenoble Alpes, Grenoble, France.,CNRS TIMC Laboratory, UMR 5525, Univ. Grenoble Alpes, Grenoble, France
| |
Collapse
|
9
|
Johnson B, Sanchez C, Woodburn K, Iglesia C. A walk through history: eponyms in gynecology- part 1. Am J Obstet Gynecol 2022. [DOI: 10.1016/j.ajog.2021.12.209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
10
|
Elardo E, Elbadri N, Sanchez C, Powell V, Smaris M, Li Y, Jacobson J, Hilbert T, Hamilton T, Wu DW. B subgroup detection in a small hospital transfusion service. Immunohematology 2021; 37:89-94. [PMID: 34170644 DOI: 10.21307/immunohematology-2021-014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The ABO blood group system includes phenotypes, or subgroups, that differ in the amount of A and B antigens present on the red blood cells (RBCs). These subgroups also differ in the A, B, or H substances present in secretions (for individuals who have the secretor phenotype). B subgroups are very rare and are less frequently reported than A subgroups. Usually, B subgroups are discovered during serologic testing when there is a discrepancy between RBC and serum grouping results. Subgroups of B are usually identified by a reference laboratory using molecular and adsorption-elution methods. This report details a case of a young, healthy, pregnant woman with a B subgroup detected by a small transfusion service using adsorption-elution methods. Serology and genotyping of the ABO gene was performed at a reference laboratory where the serology was consistent with a B subgroup, but no changes were identified in ABO gene sequencing. It is important to correctly identify B subgroups in donors and recipients to help resolve ABO discrepancies and potentially prevent ABO incompatibility in blood transfusion, thus minimizing transfusion reactions. The ABO blood group system includes phenotypes, or subgroups, that differ in the amount of A and B antigens present on the red blood cells (RBCs). These subgroups also differ in the A, B, or H substances present in secretions (for individuals who have the secretor phenotype). B subgroups are very rare and are less frequently reported than A subgroups. Usually, B subgroups are discovered during serologic testing when there is a discrepancy between RBC and serum grouping results. Subgroups of B are usually identified by a reference laboratory using molecular and adsorption-elution methods. This report details a case of a young, healthy, pregnant woman with a B subgroup detected by a small transfusion service using adsorption-elution methods. Serology and genotyping of the ABO gene was performed at a reference laboratory where the serology was consistent with a B subgroup, but no changes were identified in ABO gene sequencing. It is important to correctly identify B subgroups in donors and recipients to help resolve ABO discrepancies and potentially prevent ABO incompatibility in blood transfusion, thus minimizing transfusion reactions.
Collapse
Affiliation(s)
- E Elardo
- Department of Pathology and Laboratories , NYU Langone Hospital-Brooklyn, 150 55th Street, Brooklyn , NY 11220
| | - N Elbadri
- Department of Pathology and Laboratories , NYU Langone Hospital-Brooklyn, Brooklyn , NY
| | - C Sanchez
- Department of Pathology and Laboratories , NYU Langone Hospital-Brooklyn, Brooklyn , NY
| | - V Powell
- Transfusion Services, Department of Pathology and Laboratories , NYU Langone Hospital-Tisch, New York , NY
| | - M Smaris
- Department of Pathology and Laboratories , NYU Langone Hospital-Brooklyn, Brooklyn , NY
| | - Y Li
- Clinical Laboratories, Perlmutter Cancer Center , Lake Success, Huntington, Rego Park, and NYU Langone Health, New York , NY
| | - J Jacobson
- Department of Pathology and Laboratories , Bellevue Hospital, New York , NY
| | - T Hilbert
- Transfusion Services, Department of Pathology and Laboratories , NYU Langone Hospital-Tisch, New York , NY
| | - T Hamilton
- Transfusion Services, Department of Pathology and Laboratories , NYU Langone Hospital-Tisch, New York , NY
| | - D W Wu
- Department of Pathology and Laboratories , NYU Langone Hospital-Brooklyn, Brooklyn , NY
| |
Collapse
|
11
|
Diaby O, Sanchez C, Guerreiro E. Évaluation de la croissance microbienne au sein de mélanges de nutrition parentérale (MNP). NUTR CLIN METAB 2021. [DOI: 10.1016/j.nupar.2021.01.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
12
|
Singer P, De Waele E, Sanchez C, Ruiz Santana S, Montejo JC, Laterre PF, Soroksky A, Moscovici E, Kagan I. TICACOS international: A multi-center, randomized, prospective controlled study comparing tight calorie control versus Liberal calorie administration study. Clin Nutr 2021; 40:380-387. [PMID: 32534949 DOI: 10.1016/j.clnu.2020.05.024] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2019] [Revised: 05/18/2020] [Accepted: 05/18/2020] [Indexed: 01/25/2023]
Abstract
Since the first TICACOS study, 3 additional studies have been published comparing a medical nutrition therapy guided by indirect calorimetry to a regimen prescribed on the basis of predictive equations. A recent guidelines document included a meta-analysis including these 4 papers and found a trend for improvement (OR 0.98-1.48) in favor of medical nutrition therapy guided by indirect calorimetry in terms of survival. The aim of our study was to perform a multicenter prospective, randomized, controlled non blinded study in critically patients to assess the added value for measuring daily resting energy expenditure as a guide for nutritional support. The primary objective was to decrease infectious rate of these critically ill patients. MATERIAL AND METHODS This phase III, multi-center, randomized, controlled non blinded study was planned to include 580 newly-admitted, adult ventilated ICU patients that were planned to stay more than 48 h in the ICU departments. The nutritional support was aimed to meet 80-100% of energy requirement measured by indirect calorimetry. The calorie needs were determined by IC in the Study group and by an equation (20-25 kcal/kg ideal body weight/day) in the Control Group. The ICU staff was trained to strive to supply 80-100% of a patient's energy requirements through artificial nutrition, preferably enteral feeding. Primary endpoint was infection rate and secondary endpoints included other morbidities and mortality during ICU, at 90 and 180 days. Comparison between the study and the control group was performed using T test for equality of means (independent samples test). Correlations were performed using the Pearson correlation test. A p level of 0.05 or below was considered as significant. Cross tabs procedure used Chi-square test for testing differences in complication rates, length of stay and length of ventilation. Correlations between energy balances and complications was also be tested using one way analysis as well as ANOVA analysis between groups and within groups. Kaplan Meir curves assessed the proportion of surviving patients in the 2 groups. RESULTS Seven centers with a calorimeter available participated to the study. Due to slow inclusion rate, the study was stopped after 6 years and after inclusion of 417 patients only. From the 417 intended to treat patients, 339 followed the protocol. There was no differences between control and study groups in terms of age, sex BMI, SOFA (7.1 ± 3.1 vs 7.4 ± 3.3) and APACHE II scores (22.4 ± 7.9 vs 22.2 ± 7.4). The rate of infection (40 vs 31), including pneumonia rate, need for surgery, dialysis requirement, length of ventilation, ICU length of stay, and hospital length of stay were not different between groups. Mortality (30 in the control vs 21 in the study group) was not significantly different between groups. The decreased mortality observed in the study group when added to previous studies may have a positive effect on the meta-analysis previously published. CONCLUSION Tight Calorie Control guided by indirect calorimetry decreased the rate of infection and mortality but not significantly. This may be explained by the not relatively small sample size. There results together with the previous 4 prospective randomized studies, may improve the results of the meta-analysis exploring the effects of IC guided nutrition on mortality.
Collapse
Affiliation(s)
- P Singer
- Department of Intensive Care, Institute for Nutrition Research, Rabin Medical Center, Beillison Hospital, Affiliated to the Sackler School of Medicine, Tel Aviv University, Israel.
| | - E De Waele
- Department of Surgical ICU, UZ Brussel, Belgium.
| | - C Sanchez
- Hospital General Reina Sofía, Murcia, Spain.
| | - S Ruiz Santana
- Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain
| | - J C Montejo
- Hospital Universitario 12 de Octubre, Madrid, Spain.
| | | | - A Soroksky
- Intensive Care Unit, Wolfson Medical Center, Holon, Israel.
| | - E Moscovici
- Department of Intensive Care, Institute for Nutrition Research, Rabin Medical Center, Beillison Hospital, Affiliated to the Sackler School of Medicine, Tel Aviv University, Israel
| | - I Kagan
- Department of Intensive Care, Institute for Nutrition Research, Rabin Medical Center, Beillison Hospital, Affiliated to the Sackler School of Medicine, Tel Aviv University, Israel
| |
Collapse
|
13
|
Mehta S, Avila J, Niklitschek S, Fernandez F, Villagran C, Vera F, Rocuant R, Cardenas G, Frauenfelder A, Vieira D, Quintero S, Vijayan Y, Merchant S, Narvaez-Caicedo C, Sanchez C. Countdown to physician-free EKG interpretation. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
With the introduction of electronic medical records and other digital platforms, the classification and coding of different medical entities have become a complex, cumbersome task that is prone to diagnostic inconsistencies and errors. By incorporating Artificial Intelligence (AI) to a massive database of EKG records, we have developed an innovative methodology to accurately discriminate an EKG as “normal” or “abnormal”. We firmly believe that this algorithm sets up medicine on a path of complete computer-aided EKG interpretation.
Purpose
To present a viable AI-guided filter that can accurately discriminate between normal and abnormal EKG within a cardiologist-annotated EKG database.
Methods
An observational, retrospective, case-control study. Samples: A total of 140,000 randomly sampled 12-lead ECG of 10-seconds length with a sampling frequency of 500 [Hz] from Brazil (BR) and Colombia (CO) (divided as 70,000 normal and 70,000 abnormal EKG records per country dataset) were derived from the private International Telemedical System (ITMS) database from September 2018 to July 2019. Only de-identified records were used, records with artifacts were excluded. Preprocessing: Only the first 2s of each short lead and 9s of the long lead were considered. This data includes mobile (MOB) and transtelephonic (TTP) EKGs (50/50 ratio). Limb leads I, II and III and precordial leads V1, V2, V3 and V5 were used. The mean was removed from each lead. Training Sets: Four models were trained as depicted in the figure below. Each training dataset has 25,000 Normal and 25,000 Abnormal records, where 10% of the total records were used as a validation set. The test sets included 10,000 normal, and 10,000 abnormal records each. Testing and Class Assigning: An inception convolutional neural network was implemented; Each model was tested with 5,000 normal and 5,000 abnormal records of the corresponding country and transmission type with which they were trained. “Normal” or “Abnormal” labels were assigned to each EKG record and were compared to the cardiologists' reports; performance indicators (accuracy, sensitivity, and specificity) were calculated for each model.
Results
An overall accuracy of 82.4%; sensitivity of 88.7%; and specificity of 76.2% was achieved amongst the 4 testing models (Separate results of each training set are shown below).
Conclusion(s)
AI enables the interpretation of digital EKG records to be exercised in an organized, accurate, and straightforward manner, taking into consideration the multiple potential entities that can be diagnosed through this historical triage tool. By quickly identifying the normal records, the cardiologist is able to invest efforts in treating patients in a timely manner.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- S Mehta
- Lumen Foundation, Miami, United States of America
| | - J Avila
- Cardionomous AI, Santiago, Chile
| | | | | | | | - F Vera
- Cardionomous AI, Santiago, Chile
| | | | | | | | - D Vieira
- Lumen Foundation, Miami, United States of America
| | - S Quintero
- Lumen Foundation, Miami, United States of America
| | - Y Vijayan
- Lumen Foundation, Miami, United States of America
| | - S Merchant
- Lumen Foundation, Miami, United States of America
| | | | - C Sanchez
- Lumen Foundation, Miami, United States of America
| |
Collapse
|
14
|
Rodríguez-Heredia JM, Verburg-Baltussen L, Devender D, Durno N, Sanchez C, Ray N, Treur M, Zhuo J. AB1204 COST-EFFECTIVENESS OF ABATACEPT IN SPAIN IN SEROPOSITIVE BIOLOGIC-NAÏVE EARLY RHEUMATOID ARTHRITIS PATIENTS WITH SHARED EPITOPE. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.5333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:The HLA class II Shared Epitope (SE) is a known Rheumatoid Arthritis (RA) risk allele linked to autoantibody production and disease progression. The recent Early AMPLE study suggests an enhanced treatment benefit of abatacept (ABA) over adalimumab (ADA) in SE positive patients with early seropositive RA.1Economic implications beyond the trial follow-up duration are unknown.Objectives:To estimate the cost-effectiveness of ABA vs ADA in biologic-naive RA patients seropositive for anti-citrullinated protein antibody and rheumatoid factor based on the Early AMPLE study.Methods:We developed a microsimulation model to estimate clinical response, medical cost, quality of life and survival from a Spanish payer perspective. The model captures the patient’s disease and treatment journey using response outcomes and the Health Assessment Questionnaire (HAQ) score. Patients who fail to respond switch to the next treatment line. Six treatment lines are included to capture a lifetime horizon. Responding patients (ACR50 and EULAR response) achieve an improvement in their HAQ score. Patient mortality was modelled as a function of HAQ. For both the overall Early AMPLE population and SE+ patients, incremental monthly cost per response over 2 years and incremental cost per QALY over a lifetime were estimated. Costs were based on local tariffs in Spain.Results:Baseline characteristics for the Early AMPLE (n=80) and the SE+ (n=61) patients were well balanced between the treatment groups.2Compared to ADA, the ABA cohort had a lower cost per response and the difference was more pronounced in the SE+ population, compared to the entire Early AMPLE population for both the response criteria (Table 1). Compared with ADA, the ABA cohort showed greater quality adjusted life years (QALYs) gains, and a modest increase in cost due to a prolonged time on treatment (Table 2). The incremental cost per QALY over a lifetime fell below commonly used thresholds in Spain (25-60 thousand Euros per QALY).3Table 1.Cost per response resultsFull Early AMPLEACR50EULARABAADAABAADACost per response (€) – 2 years25,86040,65426,99340,643Incremental monthly cost per response (€)-616-569SE positiveACR 50EULARABAADAABAADACost per response (€) – 2 years24,27240,24925,33741,425Incremental monthly cost per response (€)-666-670All incremental results are for ABA – ADATable 2.Cost-effectiveness results (discounted)Full Early AMPLEACR50EULARABAADAABAADALYs*30.1430.0630.1130.03QALYs8.327.817.577.12Time on treatment (years)4.172.035.143.06Costs (€)75,54768,15785,12280,933Incremental LYs*0.080.08Incremental QALYs0.520.45Incremental Costs (€)7,3904,189Incremental cost per QALY (€)14,3089,275SE positiveACR50EULARABAADAABAADALYs*30.3830.2230.1630.09QALYs8.207.597.406.90Time on treatment (years)4.482.025.383.02Costs (€)78,11368,65187,58681,321Incremental LYs*0.150.06Incremental QALYs0.610.50Incremental Costs (€)9,4626,265Incremental cost per QALY (€)15,41012,503*LY results are presented undiscounted. All incremental results are for ABA – ADAConclusion:Compared with ADA, ABA is a cost-effective alternative and is associated with a lower 2 years cost per response for both populations. The economic benefit and quality of life gain is greater in a SE+ patient population.References:[1]Rigby W, et al. EULAR Annual Meeting, June 2019; Poster LB0008[2]Buckner J, et al. ACR/ARP Annual Meeting, Nov 2019; Poster 1424[3]Sacristán JA, et al.Gaceta Sanitaria2019Disclosure of Interests:José M. Rodríguez-Heredia: None declared, Lisanne Verburg-Baltussen Consultant of: Consultant for Bristol-Myers Squibb, Paid instructor for: Training sessions for Pharmaceutical companies, Dhanda Devender Shareholder of: BMS, Employee of: BMS, Nicholas Durno Consultant of: Consultant for Bristol-Myers Squibb, Paid instructor for: Training sessions for Pharmaceutical companies, Carlos Sanchez Shareholder of: Shareholder of Bristol-Myers Squibb, Employee of: Bristol Myers-Squibb, Neelanjana Ray Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Maarten Treur Consultant of: Consultant for Bristol-Myers Squibb, Paid instructor for: Training sessions for Pharmaceutical companies, Joe Zhuo Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb
Collapse
|
15
|
Sanchez C, Zappia J, Dierckxsens Y, Delcour JP, Henrotin Y. AB0073 BOSWELLIA SERRATA EXTRACT AND CURCUMIN INCREASE GDF15 PRODUCTION BY HUMAN PRIMARY OSTEOARTHRITIS CHONDROCYTES: A NEW MECHANISM OF ACTION. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Boswellia serrata extract (BSE) and curcumin are used to relief symptoms in osteoarthritis (OA).Objectives:This study aims to better understand the mode of action of these compounds on OA chondrocytesin vitro.Methods:Therapeutic plasmatic concentrations of the different components of BSE correspond to anin vitrorange from 25 to 100 µg/ml of total BSE (100 µg/ml of BSE corresponds to 9.2 µM of 11-keto-β-boswellic acid (KBA), 5.2 µM of acetylKBA, 22 µM de αBA, 34 µM de βBA, 4.4 µM de acetylαBA and 13.2 acetyl βBA), and between 2 to 10 µM for bioavaibility-increased curcumin. BSE (5-100 µg/ml) and curcumin (0.04 to 4 µg/ml corresponding to 0.1 to 10 µM) were tested separately on primary chondrocytes from 3 OA patients. Lactate Deshydrogenase LDH, nitrite (NO2), interleukin (IL)-6 and Growth Differentiation Factor (GDF)15 were quantified in 72h-treated supernatant using enzyme activity, Griess reaction and ELISAs, respectively.Results:No mortality was observed at the tested concentrations. BSE and curcumin both decreased concentration-dependently NO2and IL-6 production, and increased GDF15 production. For NO2production, the decrease was observed from 0.2 µg/ml of curcumin and 10 µg/ml of BSE. For IL-6 production, the decrease was observed from 1 µg/ml for curcumin and 10 µg/ml for BSE. For GDF-15, the increase was observed from 2 µg/ml for curcumin and 50 µg/ml for BSE. Maximal effect was observed at 4 µg/ml for curcumin: -67% NO2(p<0.0001), -71% IL-6 (p=0.0001) and +80% GDF15 (p<0.0001) and at 100 µg/ml for BSE: -40% NO2(p=0.0003), -70% IL-6 (p=0.0003) and +73% for GDF15 (p=0.0017).Conclusion:At therapeutic plasmatic concentrations, BSE and curcumin decreased the production of NO2and IL-6, two inflammatory mediators. Furthermore, BSE and curcumin enhanced GDF-15 production, an anti-inflammatory growth factor. GDF15 was first identified as Macrophage inhibitory cytokine-1 or NSAID-activated gene-1 (by a prostanoid-independent manner), and is known as a regulator of inflammatory, cell repair and apoptosis pathways. GDF-15 has pro-apoptotic and anti-tumorigenic activity in vitro and in vivo. It could represent a new pathway explaining the beneficial effects of BSE and the curcumin on synovium inflammation and cartilage degradation.Disclosure of Interests:christelle sanchez: None declared, Jérémie Zappia: None declared, Yvan Dierckxsens Shareholder of: Tilman SA, Employee of: Tilman SA, Jean-Pierre Delcour: None declared, Yves Henrotin Grant/research support from: HEEL, TILMAN
Collapse
|
16
|
Sanchez C, Hemmer K, Kroemmelbein N, Seilheimer B, Dubuc JE, Antoine C, Henrotin Y. AB0072 A MULTICOMPONENT MEDICATION PROMOTES CHONDROGENESIS AND REDUCES MMP-13 IN PRIMARY ARTICULAR CHONDROCYTES FROM KNEE OSTEOARTHRITIS PATIENTS IN VITRO. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:HE-1100 is a multicomponent medicinal product. Initial preclinical data potentially suggest a preventive effect on cartilage degradation.Objectives:This study aims to understand the mode of action of HE-1100 on OA chondrocytesin vitro.Methods:Primary chondrocytes were obtained from 10 knee osteoarthritis (OA) patients undergoing knee replacement surgery. The cultures were treated with 20% (v/v) HE-1100 or placebo. Samples were collected for subsequent RNA extraction using standard methods. The reads were generated with Illumina NextSeq5000 sequencer and aligned to the human reference genome (UCSC hg19) to generate the transcriptome. Differential expression analysis between HE-1100 and placebo was made in R using the DESeq2 package to identify the differentially expressed genes in the OA-associated regulatory pathways. The protein production of the selected genes was quantified by ELISA in 10 independent human OA chondrocytes cultures.Results:According to the DESeq2 analysis, HE-1100 significantly modified the expression of 13 genes in OA chondrocytes by at least 10% with an adjusted p-value < 0.05: EGR1 (+93%), FOS (+87%), NR4A1 (+43%), DUSP1 (+18%), ZFP36 (+18%), ZFP36L1 (+14%), NFKBIZ (+16%) and CYR61 (+14%) were upregulated and ATF7IP (-10%), TXNIP (-11%), C10orf10 (-12%), CLEC3A (-12%) and MMP13 (-18%) were downregulated after 24h HE-1100 treatment. HE-1100 significantly increased (2.3 fold +/-1.2 after 24h, p=0.0444 and 2.3-fold +/-1.0 after 72h, p=0.0239) the CYR61 protein production by human OA chondrocytes. After 72h, HE-1100 slightly but not significantly increased aggrecan production by 14 ± 19 % (p=0.1117) and significantly increased type II collagen pro-peptide production by 27 ± 20 % (p=0.0147). For both time points CYR61 production by OA chondrocytes was positively and significantly correlated with aggrecan (r=0.66, p=0.0004) and type II collagen pro-peptide (r=0.64, p=0.0008) production. In alginate beads culture, pro-MMP-13 was significantly decreased by HE-1100 treated cultures from day 7 to day 14 (from -16 to -25 %, p<0.05) and from day 17 to 21 (-22 %, p=0.0331) in comparison to controls.Conclusion:HE-1100 significantly modified the expression of DUSP1, C10orf10, ZFP36/L1 and CLEC3A, which are pathway mediators involved in MMP-13 expression and activation. Further, long-term (28 days) treatment with HE-1100 significantly reduced the production of pro-MMP-13, the inactive precursor of the metalloproteinase MMP-13 involved in type II collagen degradation. HE-1100 also promoted extracellular matrix formation probably through CYR61 production, a growth factor well correlated with type II collagen and aggrecan production.References:/Acknowledgments:We would like to thank the staff of the GIGA ULiège Genomic Next Generation Sequencing platform for performing the RNA sequencing and Benoit Charloteaux for his help in RNAseq data analysis.Disclosure of Interests:christelle sanchez: None declared, Kathrin Hemmer Employee of: Heel, Natascha Kroemmelbein Employee of: Heel, Bernd Seilheimer Employee of: Heel, Jean-Emile Dubuc: None declared, Christophe Antoine Employee of: Artialis, Yves Henrotin Grant/research support from: HEEL, TILMAN
Collapse
|
17
|
Peerboom S, Graff S, Seidel L, Paulus V, Henket M, Sanchez C, Guissard F, Moermans C, Louis R, Schleich F. Predictors of a good response to inhaled corticosteroids in obesity-associated asthma. Biochem Pharmacol 2020; 179:113994. [PMID: 32335139 DOI: 10.1016/j.bcp.2020.113994] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Accepted: 04/21/2020] [Indexed: 12/29/2022]
Abstract
INTRODUCTION Asthma in obese subjects is poorly understood. According to GINA guidelines, pulmonologists increase ICS in case of poor asthma control but lung volume restriction may also worsen respiratory symptoms in obese asthmatics leading to overtreatment in this subpopulation. METHODS We conducted a retrospective study on 1217 asthmatics recruited from University Hospital of Liege. 92 patients with a BMI ≥30 came at least two times at the asthma clinic (mean interval: 335 days). In this obese population, we identified predictors of good (decrease in ACQ ≥0.5) versus poor response (rise in ACQ ≥0.5) to ICS step-up therapy. RESULTS Obese asthmatics had a poorer asthma control and quality of life as compared to non-obese and exhibited reduced FVC, higher levels of blood leucocytes and markers of systemic inflammation. The proportion of asthma inflammatory phenotypes was similar to that observed in a general population of asthmatics. Among uncontrolled obese asthmatics receiving ICS step-up therapy, 53% improved their asthma control while 31% had a worsening of their asthma. Uncontrolled obese asthmatics showing a good response to increase in ICS had higher ACQ, lower CRP levels, higher sputum eosinophil counts and higher FeNO levels at visit 1. Uncontrolled obese asthmatics that worsened after increasing the dose of ICS had lower FVC, lower sputum eosinophil counts and higher sputum neutrophil counts. CONCLUSION We observed poorer asthma control in obese asthmatics despite similar bronchial inflammation. Managing obese asthmatics according to ACQ alone seems to underestimate asthma control and the contribution of restriction to dyspnea. Increasing the dose of ICS in the absence of sputum eosinophilic inflammation or in the presence of restriction or bronchial neutrophilia led to poorer asthma control. In those patients, management of obesity should be the first choice.
Collapse
Affiliation(s)
- S Peerboom
- Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, I(3) GIGA Research Group, University of Liege, Belgium
| | - S Graff
- Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, I(3) GIGA Research Group, University of Liege, Belgium
| | - L Seidel
- Medical Informatics and Biostatistics, University of Liege, Belgium
| | - V Paulus
- Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, I(3) GIGA Research Group, University of Liege, Belgium
| | - M Henket
- Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, I(3) GIGA Research Group, University of Liege, Belgium
| | - C Sanchez
- Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, I(3) GIGA Research Group, University of Liege, Belgium
| | - F Guissard
- Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, I(3) GIGA Research Group, University of Liege, Belgium
| | - C Moermans
- Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, I(3) GIGA Research Group, University of Liege, Belgium
| | - R Louis
- Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, I(3) GIGA Research Group, University of Liege, Belgium
| | - F Schleich
- Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, I(3) GIGA Research Group, University of Liege, Belgium.
| |
Collapse
|
18
|
Rogier M, Quitté B, Sanchez C, Storme T, Guerriero E, Bourdon O. Validation d’une méthode d’essai de stérilité dans une unité de production de nutrition parentérale. NUTR CLIN METAB 2020. [DOI: 10.1016/j.nupar.2020.02.429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Otandault A, Anker P, Al Amir Dache Z, Guillaumon V, Meddeb R, Pastor B, Pisareva E, Sanchez C, Tanos R, Tousch G, Schwarzenbach H, Thierry AR. Recent advances in circulating nucleic acids in oncology. Ann Oncol 2020; 30:374-384. [PMID: 30753271 DOI: 10.1093/annonc/mdz031] [Citation(s) in RCA: 62] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Circulating cell-free DNA (cfDNA) is one of the fastest growing and most exciting areas in oncology in recent years. Its potential clinical uses cover now each phase of cancer patient management care (predictive information, detection of the minimal residual disease, early detection of resistance, treatment monitoring, recurrence surveillance, and cancer early detection/screening). This review relates the recent advances in the application of circulating DNA or RNA in oncology building on unpublished or initial findings/work presented at the 10th international symposium on circulating nucleic acids in plasma and serum held in Montpellier from the 20th to the 22nd of September 2017. This year, presenters revealed their latest data and crucial observations notably in relation to (i) the circulating cell-free (cfDNA) structure and implications regarding their optimal detection; (ii) their role in the metastatic or immunological processes; (iii) evaluation of miRNA panels for cancer patient follow up; (iv) the detection of the minimal residual disease; (v) the evaluation of a screening tests for cancer using cfDNA analysis; and (vi) elements of preanalytical guidelines. This work reviews the recent progresses in the field brought to light in the meeting, as well as in the most important reports from the literature, past and present. It proposes a broader picture of the basic research and its potential, and of the implementation and current challenges in the use of circulating nucleic acids in oncology.
Collapse
Affiliation(s)
- A Otandault
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier; INSERM, U1194, Montpellier; Department of Oncology, Montpellier University, Montpellier; Regional Institute of Cancer of Montpellier, Montpellier
| | - P Anker
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier; INSERM, U1194, Montpellier; Department of Oncology, Montpellier University, Montpellier; Regional Institute of Cancer of Montpellier, Montpellier
| | - Z Al Amir Dache
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier; INSERM, U1194, Montpellier; Department of Oncology, Montpellier University, Montpellier; Regional Institute of Cancer of Montpellier, Montpellier
| | - V Guillaumon
- Regional Institute of Cancer of Montpellier, Montpellier; SIRIC, Integrated Cancer Research Site, Montpellier, France
| | - R Meddeb
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier; INSERM, U1194, Montpellier; Department of Oncology, Montpellier University, Montpellier; Regional Institute of Cancer of Montpellier, Montpellier
| | - B Pastor
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier; INSERM, U1194, Montpellier; Department of Oncology, Montpellier University, Montpellier; Regional Institute of Cancer of Montpellier, Montpellier
| | - E Pisareva
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier; INSERM, U1194, Montpellier; Department of Oncology, Montpellier University, Montpellier; Regional Institute of Cancer of Montpellier, Montpellier
| | - C Sanchez
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier; INSERM, U1194, Montpellier; Department of Oncology, Montpellier University, Montpellier; Regional Institute of Cancer of Montpellier, Montpellier
| | - R Tanos
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier; INSERM, U1194, Montpellier; Department of Oncology, Montpellier University, Montpellier; Regional Institute of Cancer of Montpellier, Montpellier
| | - G Tousch
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier; INSERM, U1194, Montpellier; Department of Oncology, Montpellier University, Montpellier; Regional Institute of Cancer of Montpellier, Montpellier
| | - H Schwarzenbach
- Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A R Thierry
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier; INSERM, U1194, Montpellier; Department of Oncology, Montpellier University, Montpellier; Regional Institute of Cancer of Montpellier, Montpellier.
| |
Collapse
|
20
|
Singer P, De Waele E, Sanchez C, Ruiz-Santana S, Montejo J, Laterre P, Soroksky A, Moscovici L, Kagan I. CN03: TICACOS International: A Multi-Center, Randomized, Prospective Controlled Study Comparing Tight Calorie Control Versus Liberal Calorie Administration Study. Clin Nutr 2019. [DOI: 10.1016/s0261-5614(19)32118-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
21
|
Barril G, Nogueira A, Alvarez G, Nuñez A, Sanchez C, Tomero J. SUN-PO151: Nutrition-Inflammation Markers and Survival in Patients with Chronic Advanced Kidney Disease (ACKD). Clin Nutr 2019. [DOI: 10.1016/s0261-5614(19)32784-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
22
|
Sanchez C, Rodriguez Aponte V, Cintron Rosado A, Molina Cruz J, Morales Irizarry J, Perez Torres Y, Pfund M, Rosado Martinez M, Santos K, Viel Torres S, Wariner M, Torres R. Concomitant Administration of Oral Iron Supplement with Antisecretory Agents among Hospitalized Adults with Iron Deficiency Anemia. J Acad Nutr Diet 2019. [DOI: 10.1016/j.jand.2019.06.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
23
|
Barril G, Nogueira A, Alvarez G, Sapiencia D, Andres N, Nuñez A, Sanchez C, Sanchez Tomero J. SUN-PO152: What is More Important in the Diagnosis of Sarcopenia Strength, Muscle Mass or Functionality? Clin Nutr 2019. [DOI: 10.1016/s0261-5614(19)32785-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
24
|
Saez R, Esteban J, Herreros B, Casas M, Huelmos A, Sanchez C, Fernandez de Velasco D, Guijarro C. Predictive performance of framingham, regicor, score, reach, b-timi and smart scales in secondary cardiovascular prevention. The airvag cohort. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
25
|
Zhang T, Sanchez C, Skvortcov P, Ferreira F, Sygletos S, Phillips I, Forysiak W, Ellis A. 86-GBaud subcarrier multiplexed 16QAM signal generation using an electrical 90 degree hybrid and IQ mixers. Opt Express 2019; 27:11819-11829. [PMID: 31053022 DOI: 10.1364/oe.27.011819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Accepted: 03/09/2019] [Indexed: 06/09/2023]
Abstract
We experimentally demonstrate an aggregate 86-GBaud (over three sub-bands and one polarization) signal generation based on subcarrier multiplexing technique using IQ mixers, an electrical 90 degree hybrid, and diplexers. The electrical hybrid allows transmitter-side digital signal processing to be simplified to pulse shaping and digital pre-emphasis. We verified the configuration by testing the performance of an 86-GBaud Nyquist-shaped 16 quadrature amplitude modulation signal with differential bit encoding. The implementation penalty assuming 7% hard-decision forward error correction is reduced to 2 dB by utilizing a 31-tap decision-directed least mean square based multiple-input multiple-output equalizer for sideband crosstalk mitigation.
Collapse
|
26
|
Poltev V, Deriabina A, Dominguez V, Sanchez C, Gonzalez E, Polteva NA. Some Problems of Computer Simulation of Non-Bonded Interactions in DNA. Biophysics (Nagoya-shi) 2019. [DOI: 10.1134/s0006350919020131] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
27
|
Sanchez C, Gamez M, Burguillo FJ, Garay J, Cabello T. Comparison of predator-parasitoid-prey interaction models for different host plant qualities. COMMUNITY ECOL 2018. [DOI: 10.1556/168.2018.19.2.4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- C. Sanchez
- Department of Biology and Geology, University of Almeria, Almeria, Spain
| | - M. Gamez
- Department of Mathematics, University of Almeria, Almeria, Spain
| | - F. J. Burguillo
- Department of Physical Chemistry, University of Salamanca, Salamanca, Spain
| | - J. Garay
- MTA Centre for Ecological Research, Evolutionary Systems Research Group, Hungary
| | - T. Cabello
- Department of Biology and Geology, University of Almeria, Almeria, Spain
| |
Collapse
|
28
|
Šantrić Milicević M, Vasić M, Edwards M, Sanchez C, Fellows J. Strengthening public health institutes: an assessment of workforce requirements in Serbia. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky218.250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- M Šantrić Milicević
- Institute of Social Medicine, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - M Vasić
- Institute of Public Health of Serbia “Dr Milan Jovanovic Batut”, ,Belgrade, Serbia
| | - M Edwards
- Department of Health, Whitehall, London, UK
| | - C Sanchez
- Department of Health, Whitehall, London, UK
| | - J Fellows
- Department of Health, Whitehall, London, UK
| |
Collapse
|
29
|
Romain M, Dache Z, Otandault A, Tanos R, Pastor B, Sanchez C, Azzi J, Tousch G, Azan S, Mollevi C, Thezenas S, Blache P, Thierry A. Quantifying circulating cell-free DNA as clinical biomarker. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Torres-Cruz R, Carrasquillo Lara J, Ferrer E, Fiorio M, Hernández Negrón G, Hernández K, Ibarra-Rodriguez I, Landrau P, Morales Hernandez R, Nieves Miranda K, Ramos Villanueva O, Sanchez C. Food Intake Reported by Nursing Staff Using the Visual Estimation Method. J Acad Nutr Diet 2018. [DOI: 10.1016/j.jand.2018.06.265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Bahri M, Dembélé K, Sassoye C, Debecker DP, Moldovan S, Gay AS, Hirlimann C, Sanchez C, Ersen O. In situ insight into the unconventional ruthenium catalyzed growth of carbon nanostructures. Nanoscale 2018; 10:14957-14965. [PMID: 30047972 DOI: 10.1039/c8nr01227j] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
We report on the in situ analysis of the growth process of carbon nanostructures catalyzed by Ru nanoparticles using syngas, a mixture of hydrogen and CO, as the carbon source at a medium temperature (500 °C). The structural modifications of the dual nanotube/nanoparticle system and the general dynamics of the involved processes have been directly followed during the growth, in real time and at the atomic scale, by transmission electron microscopy in an environmental gas cell at atmospheric pressure. After a reduction step under hydrogen and syngas, the particles became very active for the carbon growth. The growth rate is independent of the particle size which mainly influences the nanotube wall thickness. Other subtle information on the general behavior of the system has been obtained, as for instance the fact that the regular changes in the direction of the particle originate generally from the particle shape fluctuation. The main result is the evidence of a new growth mode in relation to the presence and the high instability of the ruthenium carbide phase which acts as a carbon reservoir. For the first time, a relaxation oscillation of the growth rate has been observed and correlated with the metal-carbide structural transition at the particle sub-surface.
Collapse
Affiliation(s)
- M Bahri
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), UMR 7504 CNRS - Université de Strasbourg, 23 Rue du Lœss, F-67034 Strasbourg Cedex 2, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Thierry AR, El Messaoudi S, Mollevi C, Raoul JL, Guimbaud R, Pezet D, Artru P, Assenat E, Borg C, Mathonnet M, De La Fouchardière C, Bouché O, Gavoille C, Fiess C, Auzemery B, Meddeb R, Lopez-Crapez E, Sanchez C, Pastor B, Ychou M. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Ann Oncol 2018; 28:2149-2159. [PMID: 28911069 DOI: 10.1093/annonc/mdx330] [Citation(s) in RCA: 78] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Background While tumor-tissue remains the 'gold standard' for genetic analysis in cancer patients, it is challenged with the advent of circulating cell-free tumor DNA (ctDNA) analysis from blood samples. Here, we broaden our previous study on the clinical validation of plasma DNA in metastatic colorectal cancer patients, by evaluating its clinical utility under standard management care. Patients and methods Concordance and data turnaround-time of ctDNA when compared with tumor-tissue analysis were studied in a real-time blinded prospective multicenter clinical study (n = 140 metastatic colorectal patients). Results are presented according to STARD criteria and were discussed in regard with clinical outcomes of patients. Results Much more mutations were found by ctDNA analysis: 59%, 11.8% and 14.4% of the patients were found KRAS, NRAS and BRAF mutant by ctDNA analysis instead of 44%, 8.8% and 7.2% by tumor-tissue analysis. Median tumor-tissue data turnaround-time was 16 days while 2 days for ctDNA analysis. Discordant samples analysis revealed that use of biopsy, long delay between tumor-tissue and blood collection and resection of the tumor at time of blood draw, tumor site, or type of tissue analyzed seem to affect concordance. Altogether, the clinical data with respect to the anti-epidermal growth factor receptor response (RAS status) and the prognosis (BRAF status) of those discordant patients do not appear contradictory to the mutational status as determined by plasma analysis. Lastly, we present the first distribution profile of the RAS and BRAF hotspot mutations as determined by ctDNA analysis (n = 119), revealing a high proportion of patients with multiple mutations (45% of the population and up to 5 mutations) and only 24% of WT scored patients for both genes. Mutation profile as determined from ctDNA analysis with using various detection thresholds highlights the importance of the test sensitivity. Conclusion Our study showed that ctDNA could replace tumor-tissue analysis, and also clinical utility of ctDNA analysis by considerably reducing data turnaround time.
Collapse
Affiliation(s)
- A R Thierry
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier.,INSERM, U1194, Montpellier.,Department of Oncology, Montpellier University, Montpellier.,Regional Institute of Cancer of Montpellier, Montpellier
| | - S El Messaoudi
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier.,INSERM, U1194, Montpellier.,Department of Oncology, Montpellier University, Montpellier.,Regional Institute of Cancer of Montpellier, Montpellier
| | - C Mollevi
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier.,INSERM, U1194, Montpellier.,Department of Oncology, Montpellier University, Montpellier.,Regional Institute of Cancer of Montpellier, Montpellier.,Biometry Unit, Regional Institute of Cancer of Montpellier, Montpellier
| | - J L Raoul
- Department of Medical Oncology, Paoli Calmettes Institute, Marseille
| | - R Guimbaud
- Department of Oncology, University Hospital Center of Toulouse - Hospital Rangueil-Purpan, Toulouse
| | - D Pezet
- Digestive Oncology Unit, Department of Digestive Surgery, University Hospital Center of Clermont-Ferrand, UMR Inserm/Auvergne University U1071, Clermont-Ferrand
| | - P Artru
- Jean-Mermoz Private Hospital, Lyon
| | - E Assenat
- CHRU Montpellier, St. Eloi Hospital, Montpellier
| | - C Borg
- CHRU Jean MINJOZ, Besançon
| | - M Mathonnet
- Digestive Surgery Department, Clinical Investigation Centre, University Hospital Center of Limoges, INSERM 0801, Limoges
| | | | | | - C Gavoille
- Alexis Vautrin Oncology Institute of Lorraine, Nancy
| | - C Fiess
- Digestive Oncology Department, Regional Institute of Cancer of Montpellier, Montpellier, France
| | - B Auzemery
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier.,INSERM, U1194, Montpellier.,Department of Oncology, Montpellier University, Montpellier.,Regional Institute of Cancer of Montpellier, Montpellier
| | - R Meddeb
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier.,INSERM, U1194, Montpellier.,Department of Oncology, Montpellier University, Montpellier.,Regional Institute of Cancer of Montpellier, Montpellier
| | - E Lopez-Crapez
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier.,INSERM, U1194, Montpellier.,Department of Oncology, Montpellier University, Montpellier.,Regional Institute of Cancer of Montpellier, Montpellier
| | - C Sanchez
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier.,INSERM, U1194, Montpellier.,Department of Oncology, Montpellier University, Montpellier.,Regional Institute of Cancer of Montpellier, Montpellier
| | - B Pastor
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier.,INSERM, U1194, Montpellier.,Department of Oncology, Montpellier University, Montpellier.,Regional Institute of Cancer of Montpellier, Montpellier
| | - M Ychou
- IRCM, Institute of Research in Oncology of Montpellier, Montpellier.,INSERM, U1194, Montpellier.,Department of Oncology, Montpellier University, Montpellier.,Regional Institute of Cancer of Montpellier, Montpellier.,Digestive Oncology Department, Regional Institute of Cancer of Montpellier, Montpellier, France
| |
Collapse
|
33
|
|
34
|
Sanchez C, Killgore W, Gehrels J, Alfonso-Miller P, Grandner M. 0127 Nighttime Snacking: Prevalence And Associations With Poor Sleep, Health, Obesity, And Diabetes. Sleep 2018. [DOI: 10.1093/sleep/zsy061.126] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Sanchez C, Hale L, Branas C, Gallagher R, Killgore W, Gehrels J, Alfonso-Miller P, Grandner M. 0185 Relationships between Dietary Supplement Intake and Sleep Duration, Insomnia, and Fatigue. Sleep 2018. [DOI: 10.1093/sleep/zsy061.184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | - L Hale
- Stony Brook University, Stony Brook, NY
| | - C Branas
- Columbia University, New York, NY
| | - R Gallagher
- University of Pennsylvania, Philadelphia, PA
| | | | | | | | | |
Collapse
|
36
|
Gomez GE, D'vries RF, Lionello DF, Aguirre-Díaz LM, Spinosa M, Costa CS, Fuertes MC, Pizarro RA, Kaczmarek AM, Ellena J, Rozes L, Iglesias M, Van Deun R, Sanchez C, Monge MA, Soler-Illia GJAA. Exploring physical and chemical properties in new multifunctional indium-, bismuth-, and zinc-based 1D and 2D coordination polymers. Dalton Trans 2018; 47:1808-1818. [PMID: 29322149 DOI: 10.1039/c7dt04287f] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Main group element coordination polymers (MGE-CPs) are important compounds for the development of multifunctional materials. However, there has been a shortage of studies regarding their structural, optical, catalytic, mechanical, and antibacterial properties. This work presents an exhaustive study of a set of crystalline MGE-CPs obtained from bismuth and indium metals and iminodiacetate, 1,2,4,5-benzenetetracarboxylate, and 2,2'-bipyridine as building blocks. An in-depth topological analysis of the networks was carried out. Additionally, nanoindentation studies were performed on two representative low-dimensional compounds in order to find the relationships between their structural features and their intrinsic mechanical properties (hardness and elasticity). The solid-state photoluminescence (SSPL) properties were also studied in terms of excitation, emission, lifetimes values, and CIE chromaticites. Moreover, the heterogeneous catalytic activities of the compounds were evaluated with the cyanosilylation reaction using a set of carbonylic substrates under solvent-free conditions. Finally, the inhibitory effect of the Bi-CPs on the growth of microorganisms such as Escherichia coli, Salmonella enterica serovar Typhimurium, and Pseudomonas aeruginosa, which are associated with relevant infectious diseases, is reported.
Collapse
Affiliation(s)
- G E Gomez
- Gerencia de Química, Centro Atómico Constituyentes, Comisión Nacional de Energía Atómica, Av. Gral. Paz 1499, 1650 San Martin, Buenos Aires, Argentina.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Hlavacova N, Li Y, Pehrson A, Sanchez C, Bermudez I, Csanova A, Jezova D, Franklin M. Effects of vortioxetine on biomarkers associated with glutamatergic activity in an SSRI insensitive model of depression in female rats. Prog Neuropsychopharmacol Biol Psychiatry 2018; 82:332-338. [PMID: 29269186 DOI: 10.1016/j.pnpbp.2017.07.008] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Revised: 07/09/2017] [Accepted: 07/09/2017] [Indexed: 11/27/2022]
Abstract
The aim of this study was to investigate the antidepressant activity of vortioxetine in a tryptophan (TRP) depletion female rat model of depression and compare it to that of paroxetine using doses that fully occupy the serotonin transporter (SERT). We evaluated the effects of vortioxetine on potential biomarkers associated with TRP depletion including serum aldosterone, corticosterone and IL-6 levels together with indirect indicators of glutamate neurotransmission. Female Sprague-Dawley rats were randomized to control, low TRP, low TRP/paroxetine or low TRP/vortioxetine groups. Vortioxetine and paroxetine were administered via diet (10mg/kg/day) and drinking water (10mg/kg/day) respectively for 14days. Vortioxetine but not paroxetine reversed TRP depletion-induced depressive-like behavior. Vortioxetine reduced TRP depletion-induced increases of serum corticosterone, aldosterone, IL-6 and N-methyl-d-aspartate and α7-nicotinic acetylcholine receptor expression in the amygdala and hippocampus, respectively. Paroxetine demonstrated little effect except a reduction of aldosterone. Vortioxetine but not paroxetine reversed TRP depletion-induced reductions of serum and brain kynurenic acid. In conclusion, vortioxetine, but not paroxetine, enabled reversals of TRP depletion-induced changes of depression-like behavior and markers of glutamatergic activity. These observations support the hypothesis that vortioxetine's antidepressant activity may involve mechanisms beyond SERT inhibition.
Collapse
Affiliation(s)
- N Hlavacova
- Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia
| | - Y Li
- Department of Neuroscience, Lundbeck Research USA, Inc., Paramus, NJ, USA
| | - A Pehrson
- External Sourcing and Scientific Excellence, Lundbeck Research USA, Inc., Paramus, NJ, USA
| | - C Sanchez
- Department of Neuroscience, Lundbeck Research USA, Inc., Paramus, NJ, USA
| | - I Bermudez
- School of Life Sciences, Oxford Brookes University, Oxford, UK
| | - A Csanova
- Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia
| | - D Jezova
- Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia
| | - M Franklin
- School of Life Sciences, Oxford Brookes University, Oxford, UK.
| |
Collapse
|
38
|
Azor-Lafarga A, Ruiz-González L, Parras M, Portehault D, Sanchez C, González-Calbet JM. Modified Synthesis Strategies for the Stabilization of low n Ti n O 2n-1 Magnéli Phases. CHEM REC 2018; 18:1105-1113. [PMID: 29488685 DOI: 10.1002/tcr.201700083] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Accepted: 02/16/2018] [Indexed: 11/11/2022]
Abstract
Titanium reduced oxides TiO2-x occupy, since long time, a prominent place on the landscape of binary metal oxides because of their intriguing ability to form extended defects that affect both the formation of new superlattices and different electronic behaviours. Related to these features, a wide range of practical applications has been achieved. Moved by the conviction of the great potential of understanding the influence of the reactivity, compositional variations and size effects on their functional properties, the aim of this personal account is the optimization of a recently developed strategy for the stabilization of low n Tin O2n-1 terms. In particular, we will focus on the Ti4 O7 composition as well as the incorporation of transition metals, like Mn, in order to deal with new reduced Magnéli phases.
Collapse
Affiliation(s)
- A Azor-Lafarga
- Department of Inorganic Chemistry Faculty of Chemistry, Universidad Complutense de Madrid, Madrid, 28040, Spain
| | - L Ruiz-González
- Department of Inorganic Chemistry Faculty of Chemistry, Universidad Complutense de Madrid, Madrid, 28040, Spain
| | - M Parras
- Department of Inorganic Chemistry Faculty of Chemistry, Universidad Complutense de Madrid, Madrid, 28040, Spain
| | - D Portehault
- Sorbonne Universités, UPMC Univ Paris 06, CNRS, Collège de France, Laboratoire de Chimie de la Matière Condensée de Paris, 4 place Jussieu, 75005, Paris, France
| | - C Sanchez
- Sorbonne Universités, UPMC Univ Paris 06, CNRS, Collège de France, Laboratoire de Chimie de la Matière Condensée de Paris, 4 place Jussieu, 75005, Paris, France
| | - J M González-Calbet
- Department of Inorganic Chemistry Faculty of Chemistry, Universidad Complutense de Madrid, Madrid, 28040, Spain
| |
Collapse
|
39
|
de Azambuja E, Saura C, Nuciforo P, Frantal S, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Pena L, Dubsky P, Lombard JM, Vuylsteke P, Castaneda Altamirano C, Sanchez C, Ballestrero A, Colleoni M, Santos Borges G, Ciruelos E, Bardia A, Fornier M, Boer K, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Baselga J, Gnant M. Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd5-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Taselisib is an oral, potent, selective inhibitor of Class I PI3-kinase (PI3K) alpha, gamma, and delta isoforms with enhanced activity against PIK3CA mutant cancer cells. LORELEI trial demonstrated a significant improvement in ORR (objective response rate) centrally assessed by MRI with neoadjuvant taselisib plus letrozole compared to letrozole plus placebo in all randomized patients as well as in the PIK3CA mutant cohort (Saura et al, ESMO 2017).
Methods: 334 postmenopausal women with newly diagnosed ER+/HER2-, untreated, Stage I-III operable breast cancer and evaluable tumor tissue for PIK3CA genotyping were randomized (1:1) to receive daily letrozole (2.5 mg) with either taselisib (4 mg on a 5 days on/ 2 days off schedule) or placebo for 16 weeks, followed by surgery. Tumor tissue collection was performed at baseline, week 3 (W3) and at surgery. Secondary objectives included, but were not restricted to, ORR assessed by MRI in patients with PIK3CA wild type (WT) tumors, ORR using alternative methods of tumor assessment (ultrasound, mammogram and clinical breast exam) in all patients and patients with PIK3CA mutant and WT tumors, central assessment of Ki67 at different timepoints (baseline, W3 and surgery), and the centrally derived PEPI score. Central Ki67 was assessed by two independent readers blinded to treatment arms and PIK3CA status (Vall D'Hebron Institute of Oncology, Barcelona).
Results: ORR by centrally assessed MRI was similar in the two treatment arms in patients with PIK3CA WT tumors (45.7 vs 40.4% for taselisib and placebo, respectively). ORR assessed by breast US was also significantly higher with taselisib compared to placebo in all randomized patients and in the PIK3CA mutant cohort. The highest concordance rate between MRI and other imaging modalities was found with breast ultrasound (53.7%). Centrally assessed Ki67 changes are reported in Table 1. Ki67 values decreased from baseline to W3 and from baseline to surgery in both treatment arms. No significant differences in the decrease of Ki67 values between treatment arms were detected. Unplanned analysis of Complete Cell Cycle Arrest (CCCA) at W3 was numerically higher with taselisib than with placebo in all randomized patients (49.6% vs 38.5%) and in the PIK3CA mutant cohort (60.9% vs 47.5%). Due to the variability in timing between the last dose of taselisib (median time 11 days; interquartile range 6-16 days) and tissue collection at surgery, considering the half-life of taselisib of approximately 40 hours, centrally derived PEPI score is not interpretable.
Ki67 proportional changes, %Taselisib + letrozolePlacebo + letrozoleBaseline to W3All patients-83.8-80.4PIK3CA mutant-84.5-79.1PIK3CA WT-82.8-81.1Baseline to surgeryAll patients-75.6-80.5PIK3CA mutant-71.9-79.9PIK3CA WT-78.2-81.2
Conclusion: Among the investigated alternative methods for assessing ORR, breast ultrasound performed similar to MRI. Decrease in the Ki67 values from baseline to W3 and to surgery were observed in both treatment arms. The time interval between taselisib cessation and tissue collection at surgery are being further investigated.
Clinical trial information: NCT02273973
Citation Format: de Azambuja E, Saura C, Nuciforo P, Frantal S, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Pena L, Dubsky P, Lombard JM, Vuylsteke P, Castaneda Altamirano C, Sanchez C, Ballestrero A, Colleoni M, Santos Borges G, Ciruelos E, Bardia A, Fornier M, Boer K, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Baselga J, Gnant M. Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD5-04.
Collapse
Affiliation(s)
- E de Azambuja
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - C Saura
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - P Nuciforo
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - S Frantal
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - M Oliveira
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - D Zardavas
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - A Jallitsch-Halper
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - L de la Pena
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - P Dubsky
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - JM Lombard
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - P Vuylsteke
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - C Castaneda Altamirano
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - C Sanchez
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - A Ballestrero
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - M Colleoni
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - G Santos Borges
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - E Ciruelos
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - A Bardia
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - M Fornier
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - K Boer
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - TR Wilson
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - TJ Stout
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - JY Hsu
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - Y Shi
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - M Piccart
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - J Baselga
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - M Gnant
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| |
Collapse
|
40
|
Torrente L, Sanchez C, Moreno R, Chowdhry S, Cabello P, Isono K, Koseki H, Honda T, Hayes JD, Dinkova-Kostova AT, de la Vega L. Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses. Oncogene 2017; 36:6204-6212. [PMID: 28692050 PMCID: PMC5641449 DOI: 10.1038/onc.2017.221] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2016] [Revised: 04/28/2017] [Accepted: 05/30/2017] [Indexed: 12/29/2022]
Abstract
Homeodomain interacting protein kinase-2 (HIPK2) is a member of the HIPK family of stress-responsive kinases that modulates cell growth, apoptosis, proliferation and development. HIPK2 has several well-characterised tumour suppressor roles, but recent studies suggest it can also contribute to tumour progression, although the underlying mechanisms are unknown. Herein, we have identified novel crosstalk between HIPK2 and the cytoprotective transcription factor NRF2. We show that HIPK2 is a direct transcriptional target of NRF2, identifying a functional NRF2 binding site in the HIPK2 gene locus and demonstrating for the first time a transcriptional mode of regulation for this kinase. In addition, HIPK2 is required for robust NRF2 responsiveness in cells and in vivo. By using both gain-of-function and loss-of-function approaches, we demonstrate that HIPK2 can elicit a cytoprotective response in cancer cells via NRF2. Our results have uncovered a new downstream effector of HIPK2, NRF2, which is frequently activated in human tumours correlating with chemoresistance and poor prognosis. Furthermore, our results suggest that modulation of either HIPK2 levels or activity could be exploited to impair NRF2-mediated signalling in cancer cells, and thus sensitise them to chemotherapeutic drugs.
Collapse
Affiliation(s)
- L Torrente
- Division of Cancer Research, School of Medicine, Jacqui Wood Cancer Centre, James Arrott Drive, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland
| | - C Sanchez
- Division of Cancer Research, School of Medicine, Jacqui Wood Cancer Centre, James Arrott Drive, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland
| | - R Moreno
- Division of Cancer Research, School of Medicine, Jacqui Wood Cancer Centre, James Arrott Drive, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland
| | - S Chowdhry
- Division of Cancer Research, School of Medicine, Jacqui Wood Cancer Centre, James Arrott Drive, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland
| | - P Cabello
- Division of Cancer Research, School of Medicine, Jacqui Wood Cancer Centre, James Arrott Drive, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland
| | - K Isono
- Developmental Genetics, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Japan
| | - H Koseki
- Developmental Genetics, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Japan
| | - T Honda
- Department of Chemistry and Institute of Chemical Biology & Drug Discovery, Stony Brook University, Stony Brook, NY, USA
| | - J D Hayes
- Division of Cancer Research, School of Medicine, Jacqui Wood Cancer Centre, James Arrott Drive, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland
| | - A T Dinkova-Kostova
- Division of Cancer Research, School of Medicine, Jacqui Wood Cancer Centre, James Arrott Drive, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland
| | - L de la Vega
- Division of Cancer Research, School of Medicine, Jacqui Wood Cancer Centre, James Arrott Drive, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland
| |
Collapse
|
41
|
Ortiz Comino R, Gil D, Minchole E, Diez-Ferrer M, Cubero N, Lopez-Lisbona R, Sanchez C, Ramos O, Esteban A, Dorca J, Rosell A. MA 20.08 Classification of Confocal Endomicroscopy Patterns for Diagnosis of Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.648] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
42
|
Franklin M, Hlavacova N, Li Y, Bermudez I, Csanova A, Sanchez C, Jezova D. Contrasting effects of vortioxetine and paroxetine on pineal gland biochemistry in a tryptophan-depletion model of depression in female rats. Prog Neuropsychopharmacol Biol Psychiatry 2017; 79:499-502. [PMID: 28802861 DOI: 10.1016/j.pnpbp.2017.08.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Revised: 08/07/2017] [Accepted: 08/07/2017] [Indexed: 11/29/2022]
Abstract
We studied the effects of the multi-modal antidepressant, vortioxetine and the SSRI, paroxetine on pineal melatonin and monoamine synthesis in a sub-chronic tryptophan (TRP) depletion model of depression based on a low TRP diet. Female Sprague-Dawley rats were randomised to groups a) control, b) low TRP diet, c) low TRP diet+paroxetine and d) low TRP diet+vortioxetine. Vortioxetine was administered via the diet (0.76mg/kg of food weight) and paroxetine via drinking water (10mg/kg/day) for 14days. Both drugs resulted in SERT occupancies >90%. Vortioxetine significantly reversed TRP depletion-induced reductions of pineal melatonin and serotonin (5-HT) and significantly increased pineal noradrenaline NA. Paroxetine did none of these things. Other studies suggest pineal melatonin synthesis may involve N-methyl-d-aspartate (NMDA) receptors and glutamatergic modulation. Here observed changes may be mediated via vortioxetine's strong 5-HT reuptake blocking action together with possible additional effects on glutamate neurotransmission in the pineal via NMDA receptor-modulation and possibly with added impetus from increased NA output.
Collapse
Affiliation(s)
- M Franklin
- Department of Biology and Biomedical Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK.
| | - N Hlavacova
- Institute of Experimental Endocrinology, Biomedical Research Centre of the Slovak, Academy of Sciences, Bratislava, Slovakia
| | - Y Li
- Lundbeck Research USA, Department of Biological Research, Paramus, NJ, USA
| | - I Bermudez
- Department of Biology and Biomedical Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK
| | - A Csanova
- Institute of Experimental Endocrinology, Biomedical Research Centre of the Slovak, Academy of Sciences, Bratislava, Slovakia
| | - C Sanchez
- Lundbeck Research USA, Department of Biological Research, Paramus, NJ, USA
| | - D Jezova
- Institute of Experimental Endocrinology, Biomedical Research Centre of the Slovak, Academy of Sciences, Bratislava, Slovakia
| |
Collapse
|
43
|
Huntoon V, Widrick J, Sanchez C, Kutchukian C, Cao S, Beggs A, Jacquemond V, Agrawal P. SPEG deficiency is associated with muscle weakness, triad defect, abnormal calcium handling and EC coupling. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
44
|
Wei JL, Sanchez C, Giacoumidis E. Fair comparison of complexity between a multi-band CAP and DMT for data center interconnects. Opt Lett 2017; 42:3860-3863. [PMID: 28957145 DOI: 10.1364/ol.42.003860] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Accepted: 08/21/2017] [Indexed: 06/07/2023]
Abstract
We present, to the best of our knowledge, the first known detailed analysis and fair comparison of complexity of a 56 Gb/s multi-band carrierless amplitude and phase (CAP) and discrete multi-tone (DMT) over 80 km dispersion compensation fiber-free single-mode fiber links based on intensity modulation and direct detection for data center interconnects. We show that the matched finite impulse response filters and inverse fast Fourier transform (IFFT)/FFT take the majority of the complexity of the multi-band CAP and DMT, respectively. The choice of the multi-band CAP sub-band count and the DMT IFFT/FFT size makes significant impact on the system complexity or performance, and trade-off must be considered.
Collapse
|
45
|
|
46
|
Sanchez C, Bay-Jensen AC, Pap T, Dvir-Ginzberg M, Quasnichka H, Barrett-Jolley R, Mobasheri A, Henrotin Y. Chondrocyte secretome: a source of novel insights and exploratory biomarkers of osteoarthritis. Osteoarthritis Cartilage 2017; 25:1199-1209. [PMID: 28232143 DOI: 10.1016/j.joca.2017.02.797] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Revised: 01/31/2017] [Accepted: 02/14/2017] [Indexed: 02/02/2023]
Abstract
The extracellular matrix (ECM) of articular cartilage is comprised of complex networks of proteins and glycoproteins, all of which are expressed by its resident cell, the chondrocyte. Cartilage is a unique tissue given its complexity and ability to resist repeated load and deformation. The mechanisms by which articular cartilage maintains its integrity throughout our lifetime is not fully understood, however there are numerous regulatory pathways known to govern ECM turnover in response to mechanical stimuli. To further our understanding of this field, we envision that proteomic analysis of the secretome will provide information on how the chondrocyte remodels the surrounding ECM in response to load, in addition to providing information on the metabolic state of the cell. In this review, we attempt to summarize the recent mass spectrometry-based proteomic discoveries in healthy and diseased cartilage and chondrocytes, to facilitate the discovery of novel biomarkers linked to degenerative pathologies, such as osteoarthritis (OA).
Collapse
Affiliation(s)
- C Sanchez
- Bone and Cartilage Research Unit, Arthropôle Liège, University of Liège, CHU Sart-Tilman, Belgium; The D-BOARD European Consortium for Biomarker Discovery.
| | - A-C Bay-Jensen
- The D-BOARD European Consortium for Biomarker Discovery; Department of Rheumatology, Biomarkers and Research, Nordic Bioscience, Herlev Hovedgade 207, 2730, Herlev, Denmark.
| | - T Pap
- The D-BOARD European Consortium for Biomarker Discovery; Institute of Experimental Musculoskeletal Medicine, University Hospital Munster, Domagkstrasse 3, D-48149, Munster, Germany.
| | - M Dvir-Ginzberg
- The D-BOARD European Consortium for Biomarker Discovery; Institute of Dental Sciences, Faculty of Dental Medicine, Hebrew University of Jerusalem, P.O. Box 12272, Jerusalem, 91120, Israel.
| | - H Quasnichka
- The D-BOARD European Consortium for Biomarker Discovery; Department of Veterinary Pre-Clinical Sciences, School of Veterinary Medicine, University of Surrey, Guildford, GU2 7AL, United Kingdom.
| | - R Barrett-Jolley
- The D-BOARD European Consortium for Biomarker Discovery; Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, Faculty of Health & Life Sciences, University of Liverpool, Liverpool, United Kingdom.
| | - A Mobasheri
- The D-BOARD European Consortium for Biomarker Discovery; Department of Veterinary Pre-Clinical Sciences, School of Veterinary Medicine, University of Surrey, Guildford, GU2 7AL, United Kingdom; Faculty of Health and Medical Sciences, Duke of Kent Building, University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom; Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis, Queen's Medical Centre, Nottingham, NG7 2UH, United Kingdom; Center of Excellence in Genomic Medicine Research (CEGMR), King Fahd Medical Research Center (KFMRC), Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
| | - Y Henrotin
- Bone and Cartilage Research Unit, Arthropôle Liège, University of Liège, CHU Sart-Tilman, Belgium; The D-BOARD European Consortium for Biomarker Discovery.
| |
Collapse
|
47
|
Barrio T, Castellanos E, Salas J, Arzeluz M, Lazaro C, Ortiz M, Crespo R, Sanchez C, Lizana E, Almendral J. P1723Atrial mapping during pulmonary vein pacing to detect conduction gaps in a second pulmonary vein isolation procedure. Europace 2017. [DOI: 10.1093/ehjci/eux161.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Sanchez C, Nabavi M, Judeinstein P, Doeuff S. Quelques illustrations de l’utilisation du
rayonnement synchrotron pour la caractérisation du procédé sol-gel. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1989861593] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
49
|
Lecomte M, Viana B, Sanchez C. Propriétés optiques de sondes organiques (Rhodamine 6G, Coumarine 4) et inorganiques (Eu (III), Nd (III)) dans les gels à base d'oxyde de métaux de transition. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1991880039] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
50
|
|